News & Updates

Eribulin and trabectedin show significant antitumour activity in advanced pleomorphic liposarcoma as compared with conventional chemotherapy, according to retrospective data from the Gustave Roussy cancer centre presented at ESMO SARCOMA 2023.

Treatment with four-factor prothrombin complex concentrate (4F-PCC) appears safe and effective for patients with factor Xa inhibitor-associated bleeding events, suggests a recent study.

Treatment with apremilast showed clear or almost clear skin in paediatric patients with moderate-to-severe plaque psoriasis, according to the SPROUT study presented at AAD 2023.

The combination of bevacizumab and irinotecan (BEV+IRI) as second-line treatment of glioblastoma (GBM) results in better median progression-free (PFS) and overall survival (OS) when compared with historical controls, and its toxicity profile is comparable to published data, reports a study.

Among individuals with psoriasis, oral vitamin D supplementation does not appear to have any favourable effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels, as reported in a study.

The use of antifibrotic therapy in patients with idiopathic pulmonary fibrosis (IPF) has the potential to improve survival outcome, as reported in a study.